CIPL.BO), one of the world's largest makers of antiretroviral medications to combat HIV, has been a key supplier of generic drugs to Africa. Now the Indian giant is launching a $32 million plant in Kampala, Uganda, which will produce treatments for HIV and malaria. The company became embroiled in a controversy in 2007 when the AIDS Healthcare Foundation, an American nonprofit, accused Cipla of charging more for an AIDS drug called Viraday in India than it did in Africa. Cipla denied these accusations and threatened a defamation lawsuit against AHF."> CIPL.BO), one of the world's largest makers of antiretroviral medications to combat HIV, has been a key supplier of generic drugs to Africa. Now the Indian giant is launching a $32 million plant in Kampala, Uganda, which will produce treatments for HIV and malaria. The company became embroiled in a controversy in 2007 when the AIDS Healthcare Foundation, an American nonprofit, accused Cipla of charging more for an AIDS drug called Viraday in India than it did in Africa. Cipla denied these accusations and threatened a defamation lawsuit against AHF.">

medicine

January 4, 2021
sdppf